$Kiniksa Pharmaceuticals (KNSA.US)$Revenue was generated for...

逍遥投资派 commented on a stock · Jan 14, 2023 20:53

$Kiniksa Pharmaceuticals(KNSA.US)$Revenue was generated for the first time in 2021 of 39 million dollars, and operating profit and net profit were losses for 5 consecutive years. Revenue continued to grow in the first three quarters of 2022, reaching 100 million in Q3, operating profit of 46 million in Q3, and net profit reached 220 million due to income tax rebates of 180 million dollars.

Currently, the price-earnings ratio is TTM 7.2. If you exclude the impact of income tax rebates, the price-earnings ratio TTM is actually still negative.

Since there is only one quarter of earnings data, it is impossible to determine continued profitability, so keep watching.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

See Original

Report

3578 Views

Comment

逍遥投资派

475Followers

31Following

2729Visitors